TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00997984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine hydrochloride (SPD503)
Description: dosed in AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: dosed in the AM or PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine hydrochloride
Description: Dosed in the PM
Study: NCT02775266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root planing
Description: Scaling and root planing will be done at baseline.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and Root planing
Description: Scaling and root planing will be done at baseline.
Study: NCT01361217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan
Description: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water.
Study: NCT04466384

Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.

Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
Study: NCT04442568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: early mobilisation, early oral intake, early discharge
Study: NCT01664858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT calcium score
Description: CT calcium score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT coronary angiography
Description: CT coronary angiography
Study: NCT00362882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study
Study: NCT04256473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mutant pro-urokinase
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous administration
Study: NCT01600404

Intervention type: DRUG
Intervention: antimuscarinic treatment
Study: NCT01518387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (BAY77-1931)
Study: NCT01669746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured mixed population of dermal cells
Description: A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
Study: NCT03491033

Intervention type: DRUG
Intervention: chemotherapy
Description: All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
Study: NCT02824523

Intervention type: DRUG
Intervention: aspirin
Study: NCT04550897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM7PE
Description: BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
Study: NCT03924544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decorin
Description: Antifibrotic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Antifibrotic agent
Study: NCT03175731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors
Description: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Study: NCT04476381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
Study: NCT02138812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1161909
Description: Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
Study: NCT00003869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00751712

Intervention type: DEVICE
Intervention: Cerebral oximeter sensor
Description: The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
Study: NCT03484429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Up to 60 days of peripheral nerve stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Medications, physical therapy, or other pain treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Medications, physical therapy, or other pain treatments
Study: NCT04138511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECOFISIO
Description: The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
Study: NCT04078204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Soft Capsules
Description: The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Study: NCT02073812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009 and RPX2014
Description: The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
Study: NCT00002548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 20 mg/m2 I.V. day 1 q 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 20 mg/m2 I.V. day 1 q 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days
Study: NCT01664858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray coronary angiography
Description: X-Ray coronary angiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray coronary angiography
Description: X-Ray coronary angiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray coronary angiography
Description: X-Ray coronary angiography
Study: NCT00002548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days
Study: NCT02983058

Intervention type: RADIATION
Group type: OTHER
Intervention: PET/SPECT Scan
Description: PET scan will be performed on a mCT scanner
Study: NCT00002548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: 0.5 mg/day continuous 1 - 4 q 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 0.5 mg/day continuous 1 - 4 q 5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: day 0

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
Study: NCT00506454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipidose
Description: Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
Study: NCT02855658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-1
Description: The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study: NCT02869672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hualan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hualan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hualan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
Study: NCT01828840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural morphine via PCEA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural fentanyl via PCEA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural methadone via PCEA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous morphine via PCA
Study: NCT03040128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: high-dose, intravenous minocycline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline infusion
Study: NCT05214430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 months exclusive enteral nutrition after surgery
Description: patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 months exclusive enteral nutrition after surgery
Description: patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
Study: NCT00414076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg Tablet By Mouth Daily for 12 Weeks.
Study: NCT00652171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
Study: NCT02983058

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI Scan
Description: Structural MRI will be obtained to permit co-registration of PET images
Study: NCT00652171

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amide
Description: Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
Study: NCT00948077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifater and EMB
Description: The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifater and EMB
Description: The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)
Study: NCT00959907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTULINUM TOXIN TYPE-A
Description: On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTULINUM TOXIN TYPE-A
Description: On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
Study: NCT01991483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously
Study: NCT04635202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training on elliptical device
Description: This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: group B (control group)
Description: this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
Study: NCT02799589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)